Avid raises $26M in financing

Avid Radiopharmaceuticals gained $26 million in Series C financing. The money will help Avid advance its pipeline of diagnostic molecular imaging compounds for neurological disorders, including Alzheimer's disease, Parkinson's disease and Dementia with Lewy Bodies. The financing was co-led by AllianceBernstein and Safeguard Scientifics. Last year, Avid inked a deal with Schering to develop new imaging agents for Alzheimer's.

- see the release on the financing

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.